trending Market Intelligence /marketintelligence/en/news-insights/trending/qKgd02EIGjVNXmC8fDjExw2 content esgSubNav
In This List

Takeda adds Japan, Canada in licensing deal for TiGenix Crohn's disease drug

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Takeda adds Japan, Canada in licensing deal for TiGenix Crohn's disease drug

Takeda Pharmaceutical Co. Ltd. notified TiGenix NV of its decision to exercise its option to develop and commercialize Cx601 in Japan and Canada.

The company is including the countries into the scope of its licensing agreement with TiGenix. In July, Takeda acquired the exclusive right to develop and commercialize Cx601 for complex perianal fistulas in Crohn's disease patients outside of the U.S.

Takeda's decision gives TiGenix the right to receive additional future milestone payments of up to €3 million for both countries, or 1.5 million individually, after acquiring marketing approval by respective regulatory authorities in the countries.

In addition, TiGenix is eligible to receive price reimbursement milestones for up to 2 million for both countries, or 1 million individually, as well as double-digit royalties on net sales.